Monographie - Ceftaroline fosamil

Ceftaroline fosamil

Formula chimica

Denumirea comerciala

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Zinforo

Argentina, Australia, Belgia, Brazilia, Croatia, Elvetia, Finlanda, Franta, Germania, Irlanda, Islanda, Italia, Luxemburg, Malaezia, Marea Britanie, Mexic, Norvegia, Romania, Slovenia, Spania, Suedia, Tunisia, Ungaria

Bibliografie : Ceftaroline fosamil

	tip	publicare
3249	ziar	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3520	Laborator	Cidomycin - Summary of product Chracteristics. Sanofi 2011
3549	Laborator	Amikacine B Braun - Résumé des caractéristiques du produit. B Braun 2012
3643	Laborator	Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics Sanofi 2015
3674	Laborator	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3812	ziar	Bhattacharya S, Parekh S, Dedhiya M. In-use Stability of Ceftaroline Fosamil in Elastomeric Home Infusion Systems and MINI-BAG Plus Containers. Int J Pharm Compound 2015 ; 19, 5 : 432-436.
3827	poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
4055	ziar	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4059	ziar	Madfai F, Zaidi S, Ming L, Wanandy T, Patel R. Physical and chemical stability of ceftaroline in an elastomeric infusion device. EJHP 2017 ; 25, e2
4145	ziar	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4434	ziar	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4528	ziar	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4801	ziar	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:
4968	Laborator	Zinforo 600 mg powder for concentrate for solution for infusion - Summary of Product Characteristics Updated 06-Jun-2024. Pfizer Limited 2024
4971	ziar	Coelho Mendes M, Fanfa Machioli L, Carlos G, Franco de Oliveira T, Loureiro Mendez A S. Stability of the antibiotic ceftaroline fosamil with focus on degradation products and decomposition pathways – Integrative analysis by LC-DAD, ESI-QTOF and in silico prediction J Pharm Biomed Anal 2025 ; 262: 116876.